Abstract

Despite initial findings indicating that SARS-CoV and SARS-CoV-2 are genetically related belonging to the same virus species and that the two viruses used the same entry receptor, angiotensin-converting enzyme 2 (ACE2), our data demonstrated that there is no detectable cross-neutralization by SARS patient sera against SARS-CoV-2. We also found that there are significant levels of neutralizing antibodies in recovered SARS patients 9–17 years after initial infection. These findings will be of significant use in guiding the development of serologic tests, formulating convalescent plasma therapy strategies, and assessing the longevity of protective immunity for SARS-related coronaviruses in general as well as vaccine efficacy.

Details

Title
Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2
Author
Anderson, Danielle E 1   VIAFID ORCID Logo  ; Tan, Chee Wah 1   VIAFID ORCID Logo  ; Wan Ni Chia 1 ; Young, Barnaby E 2 ; Linster, Martin 1 ; Low, JennyG H 3 ; Yee-Joo, Tan 4 ; Chen, Mark I-C 2   VIAFID ORCID Logo  ; Smith, Gavin J D 1 ; Yee Sin Leo 2 ; Lye, David C 2 ; Lin-Fa, Wang 1   VIAFID ORCID Logo 

1  Duke-NUS Medical School, Singapore, Singapore 
2  National Center for Infectious Diseases, Singapore, Singapore 
3  Singapore General Hospital, Singapore, Singapore 
4  National University of Singapore, Singapore, Singapore 
Pages
900-902
Publication year
2020
Publication date
Dec 2020
Publisher
Taylor & Francis Ltd.
e-ISSN
22221751
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1080/22221751.2020.1761267
ProQuest document ID
2508719905
Copyright
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.